Although rare, medullary thyroid cancer (MTC) exemplifies the value that ever-expanding
knowledge of molecular pathways and mechanisms brings to managing challenging …

Opinion statement Genetic assessment is crucial to address the correct treatment for
advanced medullary thyroid cancer (MTC). Multi tyrosine kinase inhibitors (mTKIs) …

Medullary thyroid cancer (MTC) is a rare tumor arising from the calcitonin-producing
parafollicular C cells of the thyroid gland, occurring either sporadically or alternatively in a …

Hereditary medullary thyroid carcinoma (MTC) represents up to one-third of MTC cases and
includes multiple endocrine neoplasia syndrome type 2A (and its variant familial MTC) and …

Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor that accounts for 2-4% of
all thyroid cancers. All inherited MTC and approximately 50% of sporadic cases are driven …

Medullary thyroid carcinoma (MTC) is a rare malignant tumor originating from thyroid
parafollicular C cells. This tumor accounts for 3%–4% of thyroid gland neoplasias. MTC may …

Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor deriving from the thyroid
parafollicular cell. Thyroidectomy continues to serve as the primary initial treatment for this …

This article summarizes the clinical features and molecular pathogenesis of medullary
thyroid cancer (MTC) and focuses on the current use of molecular, biochemical, and imaging …

Medullary thyroid cancer: therapeutic targets and molecular... : Current Opinion in Oncology
Medullary thyroid cancer: therapeutic targets and molecular markers : Current Opinion in …

Medullary thyroid carcinoma is uncommon but accounts for approximately 4 to 5 per cent of
all thyroid cancers. Although most cases are sporadic, close to one-fourth of cases result …